NL-OMON39672招募中不适用
Mindfulness Based Cognitive Therapy (MBCT) for treatment refractory anxiety disorders - MBCT for anxiety disorders
PsyQ0 个研究点目标入组 128 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 128
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- still fullfilling the criteria for an DSM IV axis 1 anxiety disorder
- •- refrain from treatment and counseling more frequently than once a month during the intervention
- •- stable use of anti-depressant medication or Benzodiazepines at leatst 3 months before inclusion
- •- Willingness to keep the dosage on a constant level during the intervention
- •-willingness to complete daily homework assignments between sessions during the MBCT course.
排除标准
- •Primary axis 1 diagnosis of substance abuse or dependence, suicidality or psychotic symptoms
研究者
相似试验
招募中
4 期
ADO CTCL-3 (Tarado): Multicentric therapy protocol for bexarotene (Targretin ®) monotherapy in pretreated CTCL stage =Ib with clear assignment to a EORTC-DiagnosisTCELLLYMPHOMAC84Mature T/NK-cell lymphomasDRKS00003693niversitätsklinikum Schleswig-Holstein Campus Kiel200
进行中（未招募）
不适用
A phase 3, double-blind, placebo-controlled, multicentre, randomised-withdrawal, long-term maintenance of efficacy and safety study of extended-release Guanfacine Hydrochloride in children and adolescents aged 6-17 with Attention-deficit/Hyperactivity DisorderADHDMedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 10037175 - Psychiatric disordersEUCTR2009-018161-12-ITShire Development Inc.510
招募中
1 期
Asciminib treatment optimization in = 3rd line CML-CPChronic Myelogenous Leukemia in chronic phase (CML-CP)MedDRA version: 21.0Level: LLTClassification code: 10009012Term: Chronic myelogenous leukemia Class: 10029104CTIS2024-511381-36-00ovartis Pharma AG205
进行中（未招募）
1 期
Study to assess the long term safety and efficacy of Guanfacine-Hydrochloride in Children and Adolescents aged 6-17 years old, with Attention- Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactive Disorder (ADHD)MedDRA version: 14.1Level: LLTClassification code 10068451Term: ADHD, combined typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10068453Term: ADHD, predominantly inattentive typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10068452Term: ADHD, predominantly hyperactive-impulsive typeSystem Organ Class: 100000004873MedDRA version: 14.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2009-018161-12-GBShire Development Inc510
进行中（未招募）
不适用
Study to assess the long term safety and efficacy of Guanfacine- Hydrochloride in Children and Adolescents aged 6-17 years old, with Attention- Deficit/Hyperactivity DisorderAttention-Deficit/Hyperactive Disorder (ADHD)MedDRA version: 15.1Level: LLTClassification code 10068451Term: ADHD, combined typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10068453Term: ADHD, predominantly inattentive typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10068452Term: ADHD, predominantly hyperactive-impulsive typeSystem Organ Class: 100000004873MedDRA version: 15.1Level: LLTClassification code 10064104Term: ADHDSystem Organ Class: 100000004873EUCTR2009-018161-12-NLShire Development Inc510